Sign In
Buy IMRA
$17.45
-0.680 (-3.75%)
At Close: Jun 03, 2026
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
11:00am, Friday, 07'th Aug 2020
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imricor Announces First Sales Collaboration With Philips
12:00am, Tuesday, 04'th Aug 2020
IMRICOR ANNOUNCES FIRST SALES COLLABORATION WITH PHILIPS.
Imricor gets distribution boost in Europe with new Philips deal - Stockhead
01:50am, Friday, 31'st Jul 2020
Medical Tech company Imricor (ASX:IMR) continued its rally from March lows with a new distribution agreement this morning. Amid a flurry of 4C filings for the June quarter, Imricor’s announcement ma
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
11:00am, Thursday, 30'th Jul 2020
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients sufferi
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
08:01pm, Monday, 29'th Jun 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
11:00am, Thursday, 25'th Jun 2020
BOSTON, June 25, 2020 -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients.
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
11:00am, Wednesday, 24'th Jun 2020
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Here is What Hedge Funds Think About IMARA Inc. (IMRA)
05:57pm, Monday, 22'nd Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation
12:44pm, Saturday, 13'th Jun 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Imara reports promising data from mid-stage trial for sickle cell treatment
11:46am, Friday, 12'th Jun 2020
Imara Inc. announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment. The Phase 2a study is testing IMR-687, an oral treatment, in adult pa
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
11:00am, Thursday, 21'st May 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Reports First Quarter 2020 Financial Results and Business Highlights
11:00am, Thursday, 07'th May 2020
Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in.
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
11:00am, Wednesday, 06'th May 2020
IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
Imara Announces Appointment of Stephen M. Migausky as General Counsel
11:00am, Monday, 04'th May 2020
Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemogl
